The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
暂无分享,去创建一个
S. Demeyer | K. Jacobs | J. Cools | C. D. de Bock | N. Mentens | A. Uyttebroeck | K. De Keersmaecker | H. Segers | N. Boeckx | J. Maertens | C. Prieto | O. Gielen | B. M. Verhoeven | J. De Bie | D. Verbeke | Jolien De Bie
[1] E. Baloglu,et al. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. , 2020, Blood advances.
[2] Y. Ohkawa,et al. Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells , 2019, eLife.
[3] M. Dimopoulos,et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. , 2019, The New England journal of medicine.
[4] G. Leone,et al. The broken cycle: E2F dysfunction in cancer , 2019, Nature Reviews Cancer.
[5] J. Shah,et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. , 2018, Blood.
[6] F. Anwer,et al. Clinical Response and Tolerability of Selinexor in Acute Myeloid Leukemia and Other Hematologic Malignancies - a Systematic Review , 2018, Blood.
[7] E. Chang,et al. Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia , 2018, Blood.
[8] D. Daelemans,et al. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas , 2018, Science Translational Medicine.
[9] Margaret S. Lee,et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death , 2018, Oncotarget.
[10] Denis Thieffry,et al. RSAT 2018: regulatory sequence analysis tools 20th anniversary , 2018, Nucleic Acids Res..
[11] E. Baloglu,et al. Clinical Implications of Targeting XPO1‐mediated Nuclear Export in Multiple Myeloma , 2018, Clinical lymphoma, myeloma & leukemia.
[12] T. Burki. Selinexor and dexamethasone in multiple myeloma. , 2018, The Lancet Oncology.
[13] S. Aerts,et al. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system , 2017, Leukemia.
[14] R. Garzon,et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. , 2017, Blood.
[15] T Terwilliger,et al. Acute lymphoblastic leukemia: a comprehensive review and 2017 update , 2017, Blood Cancer Journal.
[16] J. Taunton,et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias , 2017, Leukemia.
[17] J. Cools,et al. The genetics and molecular biology of T-ALL. , 2017, Blood.
[18] C. Hofmeister,et al. A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma , 2016 .
[19] Andrew P. Stubbs,et al. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study , 2016, PLoS medicine.
[20] Jonathan L. Schmid-Burgk,et al. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia , 2016, Clinical Cancer Research.
[21] A. Azmi,et al. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death , 2016, Oncotarget.
[22] A. Look,et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells , 2016, Leukemia.
[23] J. Byrd,et al. Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies , 2015, Leukemia.
[24] C. Riccardi,et al. GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids , 2015, Front. Endocrinol..
[25] M. Relling,et al. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia , 2015, PloS one.
[26] Stein Aerts,et al. i-cisTarget 2015 update: generalized cis-regulatory enrichment analysis in human, mouse and fly , 2015, Nucleic Acids Res..
[27] J. Byrd,et al. Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) , 2013 .
[28] C. Burd,et al. Chromatin architecture defines the glucocorticoid response , 2013, Molecular and Cellular Endocrinology.
[29] J. Cidlowski,et al. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. , 2013, The Journal of allergy and clinical immunology.
[30] J. Roganović. Acute Lymphoblastic Leukemia in Children , 2013, Journal of Indian Academy of Oral Medicine and Radiology.
[31] A. Letai,et al. KPT‐330 inhibitor of CRM1 (XPO1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia , 2013, British journal of haematology.
[32] Yuh Min Chook,et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. , 2012, Blood.
[33] A. Ferrando,et al. The molecular basis of T cell acute lymphoblastic leukemia. , 2012, The Journal of clinical investigation.
[34] Gregory E. Crawford,et al. The Hypersensitive Glucocorticoid Response Specifically Regulates Period 1 and Expression of Circadian Genes , 2012, Molecular and Cellular Biology.
[35] S. Aerts,et al. i-cisTarget: an integrative genomics method for the prediction of regulatory features and cis-regulatory modules , 2012, Nucleic acids research.
[36] D. Sullivan,et al. Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.
[37] C. Libert,et al. On the Trail of the Glucocorticoid Receptor: Into the Nucleus and Back , 2012, Traffic.
[38] Kiran C. Bobba,et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.
[39] M. Cowley,et al. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia , 2011, BMC Genomics.
[40] K. Ness,et al. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health , 2011, Expert review of hematology.
[41] C. Pui,et al. Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.
[42] M. Ohno,et al. Cajal body surveillance of U snRNA export complex assembly , 2010, The Journal of cell biology.
[43] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[44] Richard M Myers,et al. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. , 2009, Genome research.
[45] C. Riccardi,et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. , 2007, The Journal of clinical investigation.
[46] R. Crazzolara,et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. , 2006, Blood.
[47] T. Karpova,et al. Crm1 is a mitotic effector of Ran-GTP in somatic cells , 2005, Nature Cell Biology.
[48] C. Paul,et al. PHAX and CRM1 are required sequentially to transport U3 snoRNA to nucleoli. , 2004, Molecular cell.
[49] R. Haché,et al. Nuclear Export of the Glucocorticoid Receptor Is Accelerated by Cell Fusion-dependent Release of Calreticulin* , 2003, Journal of Biological Chemistry.
[50] M. Garabedian,et al. Deciphering the Phosphorylation “Code” of the Glucocorticoid Receptor in Vivo * 210 , 2002, The Journal of Biological Chemistry.
[51] N. Krett,et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] D. Livingston,et al. E2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner , 2001, Molecular and Cellular Biology.
[53] T. Hope,et al. An N‐terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IκBα , 1999 .
[54] W. Liu,et al. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. , 1999, Cancer research.
[55] R. Haché,et al. Discrimination between NL1- and NL2-Mediated Nuclear Localization of the Glucocorticoid Receptor , 1999, Molecular and Cellular Biology.
[56] P. Herrlich,et al. IκBα‐independent downregulation of NF‐κB activity by glucocorticoid receptor , 1997, The EMBO journal.
[57] A. Baldwin,et al. Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.
[58] C. Pui,et al. Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone , 2012 .
[59] R. Kofler,et al. Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia. , 2012, Molecular endocrinology.
[60] M. P. Holloway,et al. The CRM1 nuclear export protein in normal development and disease. , 2012, International journal of biochemistry and molecular biology.
[61] K. Borden,et al. mRNA export and cancer , 2012, Wiley interdisciplinary reviews. RNA.